AML

Advances in the understanding of acute myeloid leukaemia (AML) cell biology in recent years have unleashed a wave of new product development and treatment options available to patients. Eight new therapies have been approved within the past two years alone. This market evolution will continue to accelerate, with dozens of Phase 3 trails in progress addressing both adult and childhood AML treatment needs.